AstraZeneca Pharma India Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de AstraZeneca Pharma India.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	18.5%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors

Sep 18

We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Jun 03

Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

May 22

We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Apr 04

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Nov 10

AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Jul 06

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Jun 16

Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Aug 02

Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Feb 25

Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Feb 04

Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Jan 18

Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

Dec 31

We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Dec 13

Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Nov 25

Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

Nov 07

What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Oct 20

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Sep 24

If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

Aug 28

What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

Aug 02

Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Jul 12

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como AstraZeneca Pharma India no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NSEI:ASTRAZEN - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2024	13,876	959	N/A	N/A	N/A
3/31/2024	12,955	1,615	171	279	N/A
12/31/2023	11,970	1,393	N/A	N/A	N/A
9/30/2023	11,410	1,528	639	714	N/A
6/30/2023	10,661	1,330	N/A	N/A	N/A
3/31/2023	10,030	993	498	583	N/A
12/31/2022	9,502	1,100	N/A	N/A	N/A
9/30/2022	9,009	921	776	856	N/A
6/30/2022	8,625	715	N/A	N/A	N/A
3/31/2022	8,056	616	912	1,008	N/A
12/31/2021	7,839	609	N/A	N/A	N/A
9/30/2021	7,836	705	1,442	1,550	N/A
6/30/2021	7,954	849	N/A	N/A	N/A
3/31/2021	8,136	933	971	1,048	N/A
12/31/2020	7,982	756	N/A	N/A	N/A
9/30/2020	8,218	813	154	228	N/A
6/30/2020	8,208	693	N/A	N/A	N/A
3/31/2020	8,318	722	732	874	N/A
12/31/2019	8,272	725	N/A	N/A	N/A
9/30/2019	8,185	749	358	564	N/A
6/30/2019	7,714	696	N/A	N/A	N/A
3/31/2019	7,283	545	363	550	N/A
12/31/2018	6,887	478	N/A	N/A	N/A
9/30/2018	6,021	83	N/A	N/A	N/A
6/30/2018	6,050	265	N/A	N/A	N/A
3/31/2018	5,710	259	N/A	88	N/A
12/31/2017	5,319	175	N/A	N/A	N/A
9/30/2017	5,536	442	N/A	N/A	N/A
6/30/2017	5,275	176	N/A	N/A	N/A
3/31/2017	5,437	201	N/A	381	N/A
12/31/2016	5,866	279	N/A	N/A	N/A
9/30/2016	5,809	206	N/A	N/A	N/A
6/30/2016	5,711	131	N/A	N/A	N/A
3/31/2016	5,637	53	N/A	570	N/A
12/31/2015	5,529	428	N/A	N/A	N/A
9/30/2015	5,166	207	N/A	N/A	N/A
6/30/2015	4,753	-5	N/A	N/A	N/A
3/31/2015	4,690	-208	N/A	-457	N/A
12/31/2014	4,624	-615	N/A	N/A	N/A
9/30/2014	4,732	-466	N/A	N/A	N/A
6/30/2014	4,742	-199	N/A	N/A	N/A
3/31/2014	4,737	-5	N/A	-8	N/A
12/31/2013	4,545	-165	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de ASTRAZEN es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de ASTRAZEN crezcan más rápidamente que el mercado Indian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de ASTRAZEN crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de ASTRAZEN crezcan más rápidamente que el mercado de Indian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de ASTRAZEN crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ASTRAZEN se prevé que sea elevada dentro de 3 años.

AstraZeneca Pharma India Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

AstraZeneca Pharma India Limited to Report Q2, 2025 Results on Nov 13, 2024

Astrazeneca Pharma India Limited Announces Executive Changes

New minor risk - Share price stability

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors

AstraZeneca Pharma India Limited Approves Dividend for the Financial Year 2023-2024

New minor risk - Profit margin trend

AstraZeneca Pharma India Limited to Report Q1, 2025 Results on Aug 08, 2024

AstraZeneca Pharma India Limited, Annual General Meeting, Aug 08, 2024

Full year 2024 earnings released: EPS: ₹64.60 (vs ₹39.72 in FY 2023)

Astrazeneca Pharma India Limited Appoints Srikanth B.S. as Site Lead, India Operations, Effective August 1, 2024

Dividend increased to ₹24.00

We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Full year 2024 earnings released: EPS: ₹64.80 (vs ₹39.72 in FY 2023)

Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

AstraZeneca Pharma India Limited to Report Q4, 2024 Results on May 27, 2024

We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Astrazeneca Pharma India Limited Announces Board Changes

Third quarter 2024 earnings released: EPS: ₹6.32 (vs ₹11.72 in 3Q 2023)

New minor risk - Share price stability

AstraZeneca Pharma India Limited Announces Board Changes

AstraZeneca Pharma India Limited to Report Q3, 2024 Results on Feb 08, 2024

Less than half of directors are independent

Astrazeneca Pharma India Limited Appoints Hooi-Bien Chuah as Additional Director (Non-Executive)

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

AstraZeneca Pharma India Limited to Report Q3, 2024 Results on Nov 09, 2023

AstraZeneca Pharma India Limited Appoints Praveen Akkinepally as the Business Unit Head Oncology with Effect from November 1, 2023

AstraZeneca Pharma India Limited Approves Dividend for the Financial Year 2022-2023

AstraZeneca Pharma India Limited to Report Q1, 2024 Results on Aug 14, 2023

AstraZeneca Pharma India Limited Announces Executive Changes

Full year 2023 earnings released: EPS: ₹39.72 (vs ₹24.64 in FY 2022)

AstraZeneca Pharma India Limited, Annual General Meeting, Aug 14, 2023

Upcoming dividend of ₹16.00 per share at 0.4% yield

AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Full year 2023 earnings released: EPS: ₹39.72 (vs ₹24.64 in FY 2022)

Astrazeneca Pharma India Limited Announces CFO Changes

AstraZeneca Pharma India Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released: EPS: ₹11.72 (vs ₹4.57 in 3Q 2022)

AstraZeneca Pharma India Limited to Report Q3, 2023 Results on Feb 10, 2023

Less than half of directors are independent

AstraZeneca Pharma India Limited Announces Resignation of Gagandeep Singh Bedi as Managing Director, Effective December 31, 2022

Second quarter 2023 earnings released: EPS: ₹13.03 (vs ₹4.78 in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: ₹13.03 (vs ₹4.78 in 2Q 2022)

Astrazeneca Pharma India Limited Receives Import And Market Permission From The Drugs Controller General Of India For Olaparib 100Mg/150Mg

Astrazeneca Pharma India Limited Appoints Shilpa Shridhar Divekar, as an Independent Director

AstraZeneca Pharma India Limited Announces Executive Changes

AstraZeneca Pharma India Limited to Report Q1, 2023 Results on Aug 08, 2022

Full year 2022 earnings released: EPS: ₹24.64 (vs ₹37.32 in FY 2021)

Astrazeneca Pharma India Limited Proposes Final Dividend for the Financial Year 2022

Upcoming dividend of ₹8.00 per share

Full year 2022 earnings released: EPS: ₹24.84 (vs ₹37.32 in FY 2021)

AstraZeneca Pharma India Limited Recommends Final Dividend for the Financial Year 2021-22

Less than half of directors are independent

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Regio Biosciences Enters into License Agreement with Astrazeneca for Phase 2A Asset in Peripheral Artery Disease (Pad)

Astrazeneca Pharma India Limited Announces Resignation of Kimsuka Narsimhan as Independent Director, At the Close of Business Hours on February 1, 2022

Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Full year 2021 earnings released: EPS ₹37.32 (vs ₹28.88 in FY 2020)

Full year 2021 earnings released: EPS ₹37.32 (vs ₹28.88 in FY 2020)

Executive VP, President of Research & Development Oncology Jose Baselga has left the company

Sub: Astrazeneca Pharma India Limited Receives Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Osimertinib 40mg/80mg Film Coated Tablets (Tagrissotm)

Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

New 90-day low: ₹3,458

Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

BenevolentAI and AstraZeneca Achieve Collaboration Milestone with Novel Ai-Generated Chronic Kidney Disease Target

New 90-day low: ₹4,026

Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

Astrazeneca Pharma India Limited Receives Import And Market Permission In Form CT-20 For Benralizumab 30Mg/Ml Solution For Injection (Fasenra)

Daiichi Sankyo Company, Limited and AstraZeneca Announce the Initiation of TROPION-Lung01

We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

New 90-day high: ₹4,608

Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching